Statins emerge as potential cancer immunotherapy boosters

Cancer immunotherapy has transformed modern oncology by harnessing the body’s own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced durable responses in a subset of patients, raising hopes for long-term cancer control. However, for most patients, these therapies offer limited benefit, as tumors evolve mechanisms to evade immune surveillance.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup